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Abstract. Primary as well as secondary hyperparathyroidism may be associated with anemia, and parathyroidec-
tomy (PTx) may improve or even heal it. The precise link between the two conditions is still matter of dicussion. The 
purpose of the present study was to investigate possible effects of PTx on serum immunoreactive erythropoietin 
( iEPO) in secondary (group I, n = 23), and primary (group II, n = 16) hyperparathyroidism patients, and in 3 patients 
undergoing cervicotomy for thyroid mass removal (group 111). In group I patients, circulating i E P O levels rose from 
23.1 ± 4 . 8 m U / m l before PTx to 28.2 ± 5 . 0 and 245 ±125 m U / m l (mean ± S E M ) at day 7 ( p = N S ) and 14 after PTx 
(p < 0.003), respectively. Reticulocyte count increased 2 weeks after PTx: from 61,000 ±13,317 to 86,533 ± 13,462/mm3 
(p < 0.05, n = 23). In 4 of these patients serum i E P O levels could be measured again 12-24 months after PTx. They were 
slightly higher than those determined before PTx: 37 .0±8 .4 versus 31.8±13.5 m U / m l . Their hematocrits were also 
higher than before PTx: 12.8 ± 0.9 versus 11.0 ± 0 . 9 g /d l . In group II patients, serum i E P O levels remained unchanged 
after PTx: 17.5±2.0 m U / m l before PTx and 20 .0±3 .0 m U / m l 14 days after PTx. The reticulocyte count, however, 
increased significantly 2 weeks after PTx: from 25,103 ±3 ,000 to 40,827 ± 4 , 0 8 0 / m m 3 (p <0.01). In group III patients, 
serum i E P O , reticulocyte count, and hemoglobin remained stable after surgery. Since all group I patients had received 
vitamin D supplementation after PTx, we studied an additional group of 14 chronic dialysis patients (group IV) who 
received either calcitriol (1 ug/day, n = 7) or placebo (n = 7) during 14 days. The patients on calcitriol treatment, but not 
those on placebo, had a significant decrease of serum i E P O : 18.6 =b4.9 versus 16.0±4.2 m U / m l (p<0.03). In 
conclusion, PTx led to a striking increase of serum i E P O and blood reticulocytes in uremic patients with secondary 
hyperparathyroidism, and an increase of reticulocyte count, but not of i E P O , in patients with primary hyperparathy-
roidism. Marked changes of circulating P T H , extra- or intracellular calcium and phosphorus concentrations as well as 
of tissue sensitivity to EPO after PTx could all be responsible. In contrast, the surgical procedure and the therapeutic 
increase in plasma calcitriol do not appear to be involved. 
Introduction 
Erythropoietin (EPO) is a circulating glycoprotein 
with a molecular weight of approximately 34,000 daltons 
[1-3] which after neonatal life is produced by peritubular 
endothelial or interstitial cells in the cortex and outer 
medulla of the kidney [4-6]. Its principal effect is to 
stimulate red cell proliferation and differentiation in the 
bone marrow. Its production and secretion are regulated 
by the ambient oxygen pressure. Evidence indicates that 
it is the supply of and demand for oxygen by kidney cells 
that determines E P O production [7], and in addition, it 
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has recently been demonstrated using molecular biology 
methods that tissue hypoxia stimulates the renal EPO 
m R N A [8]. However, the mechanisms by which renal 
oxygen supply determines the amount of EPO m R N A are 
still unknown. 
Anemia of moderate to severe degree is a feature 
complicating almost invariably chronic renal failure 
(CRF) . Its pathophysiology is multifactorial. Several 
possible mechanisms have been described [9]: (1) de-
creased EPO production; (2) shortened red cell survival; 
(3) retained inhibitors or toxic substances that interfere 
with erythroid marrow function; (4) iron and folate defi-
ciency, and (5) blood loss. However, the most important 
cause of the anemia of end-stage renal disease is clearly 
EPO deficiency. 
With the recent development of radioimmunoassay 
techniques using antibodies directed against recombi-
nant human E P O (r-HuEPO) precise measurements of 
serum EPO levels have become posible. They show that 
levels in patients with C R F may be within the range of 
normal, low or high [10]. Relative EPO deficiency is 
clearly present in most of the uremic patients who fail to 
display an appropriate compensatory erythropoietic re-
sponse to their anemia. The recent introduction of 
r -HuEPO into clinical use has allowed to correct effec-
tively the anemia of uremic patients on intermittent 
hemodialysis treatment [11-13]. 
Besides the above-mentioned mechanisms including 
inappropriate E P O production, secondary hyperparath-
yroidism has also been considered as a possible cause in 
the development of anemia during C R F [14-17]. This 
consideration results from observations that primary hy-
perparathyroidism is sometimes associated with anemia 
[18, 19]. Conversely, surgical ablation of parathyroid ad-
enoma has been shown to correct the anemia observed 
during primary hyperparathyroidism [18, 19] and to im-
prove the anemia in about 50% of parathyroidectomized 
patients with C R F [20-22]. The way by which hyperpar-
athyroidism worsens and parathyroidectomy (PTx) im-
proves renal anemia is not well understood. It could 
involve a direct inhibitory effect parathyroid hormone 
(PTH) on erythropoiesis or the induction of marrow 
fibrosis. A possible interference with EPO production 
has so far not been considered. 
It seemed reasonable therefore to determine the kinet-
ics of serum EPO levels in primary and secondary hyper-
parathyroidism after PTx as well as the other main he-
matological parameters. Moreover, we have examined a 
possible effect of calcitriol treatment on serum EPO 
levels in uremic hemodialysis patients. 
Patients and Methods 
Patients 
Group I. Twenty chronica l ly uremic patients undergoing mainte-
nance hemodialysis . 1 patient on chronic ambulatory peritoneal 
dialysis, and 2 patients with advanced C R F (Ccr<10 m l / m i n ) not 
yet on dialysis were referred to our center for the indicat ion of 
surgical correction o f severe secondary hyperparathyroidism. Their 
mean age was 50.7 ± 3.3 years ( ± S E M ) . Eleven out of the 23 patients 
were females and 12 males. M e a n durat ion of hemodialysis treat-
ment was 8.0 ± 1 . 0 years. The etiology of renal disease was renal 
vascular disease in 3 patients, g lomerulonephri t is in 5, polycyst ic 
kidney disease in 5, chronic interstitial nephropathy in 6, renal 
cortical necrosis in 1 and unknown in 3. Because of severe secondary 
hyperparathyroidism PTx was indicated for all patients, based on 
c l in ica l , b iochemica l , radio logica l , and histological (bone biopsy) 
criteria and failure o f previous medical therapy. Subtotal PTx (abla-
tion of 3 glands and o f 1 h t o 2 3 of the 4th) was performed in 10 patients 
and total PTx fol lowed by immediate autografting o f several parath-
yroid fragments into the forearm brachioradia l is muscle in the other 
13 patients. A l l parathyroid glands were identified his tological ly on 
frozen section before excis ion. F o l l o w i n g PTx, ca lc ium (CaCO.O 
and vi tamin D ( l a O H vi tamin D ? ) supplementat ion was required by 
all patients to br ing plasma total ca lc ium concentration back to 
levels above 2.0 mmol /1 . Dia lys is patients were treated dur ing their 
hospital stay by conventional bicarbonate hemodialysis (4-5 h 
thrice weekly). The dialysate ca lc ium concentration was 1.75 
mmol /1 . 
Seven patients with severe symptomatic anemia (hematocrit 
between 16 and 30%) required b lood transfusions before operation 
to maintain hematocrit at about 30-35%. None of the patients 
suffered from sickle cell anemia or myeloproliferative disease. 
None of the patients received antianemic treatment such as vitam-
ins, ferrous salt, androgen or r - H u E P O . The duration of fo l low-up 
in the hospital was 3 weeks for each patient, 1 week before and 2 
weeks after PTx . 
Group II. Sixteen subjects with normal renal function were 
referred for surgical correction o f pr imary hyperparathyroidism. 
Their mean age was 62.8 ± 4 . 6 years. Ten out of the 16 patients were 
females and 6 males. Subtotal PTx (ablation o f an adenoma) was 
performed in all patients. Parathyroid adenomas were identified 
his tological ly on frozen section before excis ion. F o l l o w i n g PTx, 
ca lc ium ( C a C 0 3 ) and vi tamin D ( l a O H vi tamin D 3 ) supplementa-
t ion was required only by some patients to maintain plasma total 
ca lc ium concentration above 2.0 mmol /1 . A l l the patients were 
fol lowed dur ing 2 weeks after PTx . 
Group III. Three subjects (1 female, 2 males) with normal renal 
function were referred for surgical correction of a thyroid mass. 
Thei r mean age was 59.8 ± 9 . 1 years. Cerv ico tomy was fol lowed by 
ablat ion of a thyroid nodule in all patients. C a l c i u m or vi tamin D 
supplementation was not required. The three patients were fol lowed 
dur ing 2 weeks after the cervical surgery. 
Group IV. Fourteen chronica l ly uremic patients undergoing 
maintenance hemodialysis were studied in order to investigate the 
influence of calci t r iol on E P O kinetics. They had a mean age of 
43.9 ± 3.7 years. H a l f of the patients were females and the other half 
males. This group was subdivided in a random fashion into two 
groups of 7 patients each (groups A and B). Ora l treatment with the 
active vi tamin D metabolite, ca lc i t r io l (1 ug /day during 14 days) was 
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administered to half of the patients (group A ) . Simultaneously, the 
other half (group B) patients received a placebo. G r o u p A patients 
had a mean age of 3 9 . 0 ± 5.18 years. They were 3 females and 4 
males. Mean duration of hemodialysis treatment was 4.3 ± 2.4 years. 
The etiology of renal disease comprised glomerulonephrit is (5 pa-
tients) and hereditary nephropathy (2 patient). G r o u p B patients 
had a mean age of 48.9 ± 4.8 years. They were 4 females and 3 males. 
M e a n duration of hemodialysis treatment was 1 .4±0.5 years. The 
etiology of renal disease comprised glomerulonephrit is (2 patients), 
polycystic kidney disease (1 patient), interstitial nephropathy (3 
patients) and unknown (1 patient). None of the patients received 
oral vitamin D supplementation during the month prior to study. 
Patients were treated by conventional acetate or bicarbonate hemo-
dialysis (4-5 h thrice weekly). The dialysate calcium concentration 
was 1.75 mmol/1 . None of the patients required b lood transfusions 
during the study. None of the patients suffered from another type of 
anemia, inflammatory disorders or myeloproliferative diseases. 
None of the patients received antianemic treatment such as folic 
acid, ferrous salt, androgen or r - H u E P O . 
A l l the patients gave their informed consent to participate in 
these studies. 
Hematological Parameters 
B l o o d sampling was always performed after a 12-hour fast, 
before a hemodialysis session in uremic patients undergoing hemo-
dialysis treatment. B l o o d hemoglobin (Hb), packed cell volume 
( P C V ) , platelets, reticulocytes and serum immunoreactive E P O 
( i E P O ) concentration were measured during the week before and 2 
times after cervicotomy (day 7 and 14) in all patients of groups I, II 
and III. Serum i E P O concentration was again measured 12-24 
months after PTx in 4 group I patients. G r o u p IV patients had only 
two blood samples for the determination of serum i E P O , namely 
before and at the end of calcitr iol or placebo administration (day 0 
and 14). 
Biochemical Parameters 
Plasma total ca lc ium and phosphorus levels were measured 
during the week before PTx and at least 2 times after cervicotomy 
(day 7 and 14) in all patients of groups I, II, and III. In group IV 
patients they were measured during the week before calci tr iol or 
placebo treatment and thrice a week thereafter until the end of 
study. Plasma immunoreactive P T H ( i P T H ) was measured before 
and 14 days after the surgery in the three first groups of patients. 
Basal plasma a luminum, was measured in all 23 patients of group I, 
and plasma A l after deferoxamine ( D F O ) infusion in 22 group I 
patients. Plasma AI after D F O (1-hour infusion of D F O of 40 mg /kg 
body weight was determined at 2, 4, 8, 24, and 48 h after start of 
infusion. 
Plasma calcium was determined using atomic absorption spec-
trometry, plasma phosphorus using a Technicon Auto Analyzer . 
Plasma AI was determined using atomic absorption spectrometry 
with a graphite oven, and plasma i P T H using an antibody directed 
against the entire P T H molecule (normal values: 10-65 pg/ ml). 
Serum i E P O concentrations were determined by r a d i o i m m u -
noassay as described elsewhere [23]. N o r m a l values in healthy 
adults with this assay are comprised between 11 and 31 m U / m l 
(95% confidence in terval : mean, 17.9 m U / m l , n = 84). T w o sam-
ples conta in ing more than 100 m U ml i E P O were also assayed in 
the polycythemic mouse assay for E P O . exactly as described 
previously [23]. 
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Fig . 1. Serum i E P O before and at day 7 and at day 14 after PTx in 
22 hemodialysis patients is shown. 
Stat is t ica I An a I\ >s is 
A l l results are given as the means ± S E M . Statistical analysis was 
performed using one-way analysis of variance, paired or unpaired 
Student's test or Mann-Whi tney U test as appropriate. The signifi-
cance of the magnitude of correlation coefficients between bio-
chemical values was assessed by linear regression analysis. 
Results 
Hem a tologica / Pa ra meters 
Patients of group I had a marked increase of serum 
iEPO concentration after PTx. Mean circulating i E P O 
before PTx (1-7 days) was 23.1 ± 4 . 8 m U / m l (n = 23). The 
highest (71 m U / m l ) and lowest (6 mU/ml) values were 
observed in 2 patients with hypertensive nephropathy. At 
day 7 and 14 after PTx, mean serum iEPO concentration 
was 28.2 ± 5.0 and 245 ± 125 m U / m l , respectively (fig. 1). 
The difference between pre-PTx and post-PTx values at 
day 14 was highly significant (p< 0.003, table 1). It must 
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Table 1. Effect of PTx and ablation o f a thyroid nodule on serum Table 2. Effect of PTx and ablation of a thyroid nodule, on 
i E P O levels ( m U / m l ) reticulocyte count per m m 3 of whole b lood 
Before 
surgery 
7 days after 
surgery 
14 days after 
surgery 
Before 
surgery 
14 days after 
surgery 
G r o u p I 
(secondary 
hyperparathyroidism) 
23.1 ± 4 . 8 
(n = 23) 
28.2 ± 5 . 0 
(n = 23) 
245 ± 1 2 5 * 
(n = 23) 
G r o u p I 
(secondary 
hyperparathyroidism) 
6 1 , 0 0 0 ± 13,317 
(n = 23) 
86,533 ± 1 3 , 4 6 2 * 
(n = 23) 
G r o u p II 
(primary 
hyperparathyroidism) 
1 7 . 5 ± 2 . 0 
(n=16) 
2 0 . 0 ± 3 . 0 
(n=16) 
G r o u p II 
(primary 
hyperparathyroidism) 
25,103 ± 3 , 0 0 0 
(n=16) 
40,827 ± 4 , 0 8 0 * * 
(n=16) 
G r o u p III 
(subtotal 
thyroidectomy) 
16.0 ± 1 . 2 
(n = 3) 
20.3 ± 1 . 8 
(n = 3) 
1 9 . 0 ± 2 . 0 
(n = 3) 
G r o u p III 
(subtotal 
thyroidectomy) 
44,663 ± 17,868 
(n = 3) 
38,205 ± 2 3 , 3 6 6 
(n = 3) 
Values are means ± S E M . *p <0.003. Values are m e a n s ± S E M . *p<0.05; **p<0.01 
Table 3. Long-term fol low-up of H b and serum i E P O after PTx in 4 uremic hemodialysis patients 
Before surgery 1 week after PTx 2 weeks after PTx 1 year after PTx 2 years after PTx 
Hemoglob in , g % 11.0 ± 0 . 9 10.4 ± 0 . 6 9.7 ± 0 . 9 1 2 . 0 ± 0 . 8 12.8 ± 0 . 9 
i E P O , m U / m l 3 1 . 8 ± 13.5 33.3 =t 12.8 382 ± 1 3 5 40.6 ± 12.8 3 7 . 0 ± 8 . 4 
Values are means ± S E M . 
also be noted that the greatest increases in serum iEPO 
concentration 14 days after PTx have been observed only in 
those patients who did not receive a blood transfusion after 
surgery. Eighteen out of the 23 patients presented a serum 
iEPO increase. In addition, we have measured serum iEPO 
levels and Hb again in 4 group I patients 12 and 24 months 
after PTx. Mean serum iEPO values were slightly higher 
than that determined before PTx: 37.0±8.4 versus 
31.8±13.5 mU/ml . These 4 patients showed a marked in-
crease of Hb 2 years after PTx, and none of the patients had 
received blood transfusion during this period: from 
11.0 ± 0.9 to 12.8 ±0 .9 g/dl (table 2). Another patient re-
quired intermittent phlebotomy due to polycythemia 6 
months after PTx. In 2 patients with more than 100 mU/ml 
iEPO 14 days after PTx, serum was also assayed in the 
polycythemic mouse assay for EPO. These measurements 
confirmed the results obtained by radioimmunoassay, thus 
indicating that circulating iEPO material contained full 
bioactivity (1,635 ± 789 vs. 1,750 ± 413 mU/ml). 
There was no significant difference between mean 
P C V and mean Hb values before and 14 days after PTx in 
group I patients. Mean P C V was 27.4 ± 2.2% before PTx, 
28.8 ±1.4% at day 7, and 27.2 ± 1.5% at day 14 after PTx, 
respectively. Mean Hb values were 9.2 ±0 .7 g /d l before 
PTx, 9.7 ± 0 . 4 g /dl at day 7, and 9.2 ±0 .5 g/dl at day 14 
after PTx, respectively. A l l the patients had anemia 
(PCV < 30%), only 1 patient had a P C V > 30%. A modest, 
but significant increase in reticulocyte count was ob-
served at day 14 after PTx from 61,000 zb 13,317 to 
86,533 ± 13,462/mm3 (p < 0.05, n = 23, table 3). 
Figure 2 shows the follow-up of serum iEPO, reticulo-
cyte count, Hb, and plasma i P T H after PTx in a represen-
tative patient. The marked decrease of plasma i P T H 
immediately after PTx was associated with a parallel 
increase of serum i E P O and reticulocyte count. Figure 3 
depicts the follow-up of the same parameters in an other 
patient who had only a partially effective PTx. The pro-
gressive decrease of plasma i P T H was consistent but it 
was much slower compared with the patient of figure 2. 
The degree of the decrease of plasma i P T H and phospho-
rus concentration correlated with the increase of serum 
i E P O and reticulocyte count. 
A n increase in platelet count was observed after PTx 
in all patients of group I, which was statistically signifi-
cant from 7-day onwards: 204 ,250±22,294/mm 3 before 
PTx, 223,100 ± 23,178/mm 3 at day 7 after PTx and 
256,727 ± 4 0 , 3 2 0 / m m 3 at day 14 after PTx, respectively 
(p < 0.03 and p < 0.006, respectively, n = 23). 
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Group 11 patients operated for primary hyperparathy-
roidism had a modest, but not significant, increase of 
serum i E P O concentration 14 days after PTx: 17.5 ± 2 . 0 
versus 20.0 ±3 .0 m U / m l (n = 16, p = NS, table 1). Mean 
PCV and mean Hb values did not change significantly after 
PTx. Mean PCV was 38.2 ± 3.5% before PTx, 35.9 ± 5.4% at 
day 7, and 36.8 ±4 .5% at day 14 after PTx, respectively. 
Mean Hb values were 13.0±1.3 g/dl before PTx, 12.6 ±1.4 
g/dl at day 7, and 12.4 ±1.4 g/dl at day 14 after PTx, 
respectively. Twenty-five percent, that is 4 out of 16 patients, 
in this group had an anemia ( P C V < 35%). A significant 
increase in reticulocyte count was apparent 2 weeks after 
PTx: from 25,103 ±3 ,000 /mm 3 to 40,827 ±4 ,080 /mm 3 
(p < 0.01, n = 16, table 3). There was also an increase in 
platelet count after PTx: from 274,440±20,280/mm 3 be-
fore PTx to 279,940 ± 67,290 at day 7 and to 310,940 ±71,860 
at day 14 after PTx, respectively (p < 0.07, n = 16). 
Group III patients, operated upon for a thyroid mass, 
had no apparent perturbation of calcium metabolism. 
Similary to primary hyperparathyroidism patients, they 
had no increase of serum i E P O concentration 14 days 
after PTx: 16.0 ± 1.2 versus 19.0 ± 2.0 m U / m l (n = 3, table 
1). Mean P C V and mean Hb values did also not change 
after PTx: mean P C V was 39 .2±3 .5% before PTx, 
37.6 ± 2.3% at day 7, and 37 .4± 2.4% at day 14 after PTx, 
respectively, and mean Hb values 13.0±1.4 g/dl before 
PTx, 12.4 ± 1.0 g /d l at day 7, and 12.3 ±1.0 g/dl at day 14 
after PTx, respectively. Reticulocyte count did also not 
change 2 weeks after PTx, 44,663 ± 17,868 versus 
38,205 ±23 ,366 /mm 3 (table 3). There was a slight increase 
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Fig. 4. a Fo l low-up after PTx of mean plasma phosphate of 
patients with primary hyperparathyroidism ( • ) and secondary hy-
perparathyroidism (•) . b Fo l low-up of mean plasma total calcium 
after PTx in the same groups o f patients. 
in platelet count after PTx: from 255,330± 122,320/mm3 
before PTx to 277,000 ± 151,000/mm3 at day 7, and to 
280,000 ±95 ,390/mm 3 at day 14 after PTx, respectively. 
Patients of group IV had a slight, but statistically 
significant decrease of serum i E P O after calcitriol ther-
apy (group A ) : from 18.6 ± 4.9 to 16.0 ± 4.2 m U / m l (n = 7, 
p<0.03). In group IV patients who received placebo 
(group B) no difference was found between mean serum 
i E P O before as compared to after placebo intake: 
11.4±1.4 versus 12.0 =h2.1 m U / m l . No significant differ-
ence of serum i E P O concentration existed between 
groups A and B at the start of study. There was no 
significant difference between mean P C V and mean Hb 
values before and after calcitriol therapy in both groups. 
Plasma Biochemistry 
Figure 4 shows the follow-up of plasma phosphate for 
group I and group II of patients after PTx. In secondary 
hyperparathyroidism (group I), mean plasma phosphate 
before PTx was 2.17 ±0.15 mmol/1. It decreased to 
0.82 ±0.10 mmol/1 immediately after PTx (p< 0.001, 
n = 23). By contrast, in primary hyperparathyroidism 
(group II), mean plasma phosphate before PTx was 
0.73 ±0 .04 mmol/1, and it increased to 0.97 ±0 .06 2 
weeks after PTx (p < 0.01, n = 16). Figure 3 also depicts the 
course of mean plasma total calcium in both groups of 
patients. In group I, pre-PTx mean plasma total calcium 
was 2.78 ±0 .05 mmol/1. It decreased to 1.80 ±0 .06 
mmol/1 immediately after PTx. By contrast, in group II 
pre-PTx mean plasma total calcium was 2.89 ±0 .04 
mmol/1. It decreased to 2.06 ±0.14 mmol/1 5 days after 
PTx. The former patients required high doses of calcium 
carbonate to maintain the calcemia above 2.00 mmol/1 
whereas group II patients did not. 
Group I patients had a mean pre-PTx plasma i P T H 
concentration of 906 ± 68 pg/ml . It decreased to 120 ± 17 
pg/ml 2 weeks after PTx. Group II patients had a mean 
pre-PTx plasma i P T H concentration of 148 ± 89 pg/ml . It 
decreased to 37 ±31 2 weeks after PTx. Group I patients 
had significantly higher pre-PTx plasma i P T H levels than 
group II patients as well as a higher degree of plasma 
i P T H decrease after PTx. In group III plasma i P T H did 
not change after surgery: 45 ± 22 versus 38 ± 17 pg/ml . 
In group I patients, basal plasma A l concentration 
before PTx was 2.02 ±0.25 u.mol/1 (n = 22). 
Amongst group IV patients, group A had a signifi-
cant increase of plasma total calcium and phosphorus at 
day 15 after calcitriol administration: 2.34±0.02 and 
1.58±0.17 mmol/1 before treatment versus 2.50±0.07 
and 2.00 ±0 .26 mmol/1 at day 15 (p<0.01 and p<0.03, 
respectively, n = 7). No such increase of plasma total 
calcium or plasma phosphorus was observed in group B 
patients. 
Correlations 
We tried to establish correlations between several 
plasma parameters in group I and group II patients. In 
either group, no relation was found between plasma total 
calcium, plasma phosphorus, and plasma i P T H before 
PTx and serum i E P O levels before PTx. In the two groups 
of patients, we were also unable to observe a relation 
between the maximum decrease in plasma total calcium 
after PTx and serum i E P O levels before or after PTx. 
Moreover, the decrease in plasma phosphorus after PTx 
in group I patients was not related to the increase in 
serum i E P O , and the increase in plasma phosphorus after 
PTx in group II patients was not related to serum i E P O 
after PTx. There was no relation between basal plasma A l 
or the delta of A l increase after D F O infusion and serum 
i E P O before or after PTx in group I patients. In patients 
of group I no relation was found between serum i E P O 
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levels and P C V before or after PTx. By contrast, in group 
II patients in whom this relation was also absent before 
PTx, a significant negative relation was found 2 weeks 
after PTx (p< 0.003). No relation could be detected be-
tween serum i E P O and blood reticulocytes or between 
the increase in serum i E P O and the change in circulating 
reticulocytes. 
Discussion 
This study demonstrates the novel finding of a stri-
king, significant increase in serum i E P O concentration 
immediately after the surgical correction of severe secon-
dary hyperparathyroidism in chronic hemodialysis pa-
tients. Such an increase was not observed after the surgi-
cal correction of primary hyperparathyroidism or after 
cervicotomy for thyroid surgery. In an additional study, 
we found a slight, but significant, decrease of circulating 
i E P O after a 14-day, high-dose calcitriol treatment in 
dialysis patients which was not observed in patients re-
ceiving placebo. 
Priorto the surgical intervention, serum i E P O levels in 
the uremic patients undergoing hemodialysis and in pa-
tients with primary hyperparathyroidism were inapprop-
riately low in relation to hematocrit values. No correla-
tion existed between serum i E P O levels and hematocrit 
values before PTx. This observation has already been 
made by other authors [24-26] in the condition of secon-
dary hyperparathyroidism. We found that this was also 
true for patients with primary hyperparathyroidism. Af-
ter surgical correction of primary hyperparathyroidism 
serum i E P O increased slightly, but not significantly. 
However, a relationship between EPO and hematocrit 
became then apparent. 
Hyperparathyroidism may contribute to renal anemia 
either by a direct inhibitory effect on erythropoiesis or 
through osteitis fibrosa or both. Evidence of an improve-
ment of anemia has been obtained in several dialysis 
patients after PTx [20-22] as well as after PTx in patients 
with primary hyperparathyroidism [17, 18]. In uremic 
patients, the improvement of the anemia after PTx was 
associated with a regression of marrow fibrosis [20], low-
ering of the serum phosphate level [27], and a decrease of 
plasma i P T H [14,19]. However, a direct relation between 
plasma i P T H levels and the degree of anemia or inhibi-
tion of erythropoiesis could never be demonstrated [20, 
28, 29]. 
As to serum i E P O concentration, it has been found to 
slightly increase 9-12 months after PTx in one study [29]. 
The present short-term study in the majority of uremic 
patients was not aimed at confirming the improvement of 
anemia which we have shown to occur after PTx in a 
previous study in hemodialysis patients [20]. Interes-
tingly, it shows a marked increase of serum i E P O after 
PTx. Since it is the bioavailability of EPO that is the 
limiting factor for erythropoiesis during C R F , the in-
crease of serum i E P O after PTx could account for the 
improvement of anemia in uremic patients. Presently, we 
do not know how long the rise of serum i E P O lasts after 
PTx. Data obtained from 4 patients suggests that 1-2 
years after PTx, serum i E P O levels have more or less 
declined to the preoperative values. 
More interestingly, our findings indicate that the 
uremic organism is in principle capable of producing 
EPO in amounts that should be sufficient to compensate 
the anemia. This finding is in accordance with a recent 
observation which states that acute hypoxia elicits up to 
10-fold increases of serum E P O levels in severely anemic 
children with C R F [25]. However, the time course of the 
increase in serum i E P O levels was different between 
these uremic children and our dialysis patients, in that the 
increase was less marked and more rapid in the children 
and that i E P O values returned to lower levels already 
24-28 h after hypoxic stress. 
In our study we did hot obtain evidence for the source 
of EPO nor for the mechanism by which PTx could 
elevate serum EPO levels. Several mechanisms can be 
considered. The possibility that the rise of serum iEPO is 
an unspecific side effect of the surgical intervention is 
unlikely for at least two reasons. Firstly, two control 
groups, namely, 2 patients who received abdominal surg-
ery [30], and 3 patients of ours who underwent cervicot-
omy for thyroid mass, failed to increase serum i E P O after 
surgery. It is also of note that blood gases did not change 
following PTx. Secondly, the data on serum i E P O levels 
obtained after renal allotransplantation by others [31] and 
ourselves [32] also suggest that surgery has no effect per se 
on serum EPO levels. It is the lag time and the amplitude 
of the increase of serum EPO levels that are significantly 
different between renal transplantation and PTx. 
Blood loss during surgery could have constituted the 
main stimulus for EPO production. Walle et al. [26] 
showed that only a 58% rise in serum i E P O levels oc-
curred in hemodialysis patients in response to a 25% drop 
in hematocrit resulting from spontaneous hemorrhage. 
This response was much less marked than that reported 
for chronically anemic patients without renal failure. 
Such a hypothesis can therefore be reasonably excluded 
since the increase of circulating i E P O concentrations in 
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our patients was much greater than that described by 
Walle et al., for a decrease in hematocrit that was either 
minor or absent. In our study, even patients who had 
received blood transfusions before and after PTx showed 
an increase of serum i E P O levels. 
A decrease of plasma total phosphorus could be 
involved. Hyperphosphatemia, which is constantly ob-
served in uremic patients with severe secondary hyper-
parathyroidism, leads to an increase in red cell glyco-
lytic rate and a rise in adenosine triphosphate and 
2 , 3 - D P G . This rise leads to a decrease in the hemoglo-
bin-oxygen affinity ('shift to the right') of the hemoglo-
bin-oxygen dissociation curve [33], thus increasing tis-
sue oxygenation. This may contribute to decreased 
E P O production and hence to anemia by reducing the 
hypoxic stimulus in the remaining renal cortex or the 
liver. Furthermore, in vitro studies have demonstrated 
that adenosine may modulate E P O release from renal 
cells [34] and in vivo studies have shown that the nonse-
lective adenosine antagonist, theophylline, could pre-
vent the polycythemia often observed after renal trans-
plantation [35, 36]. Conceivably, correction of hyper-
phosphatemia by PTx would have the opposite effect 
on red cell adenosine triphosphate and 2 ,3-DPG levels 
and thereby augment E P O production and Hb levels. 
In contrast, the absence of an increase in serum i E P O 
after PTx in the patients with primary hyperparathy-
roidism could be explained at least partially by the 
significant increase in plasma phosphorus and in 
2 ,3 -DPG levels after PTx. 
The chronically elevated serum calcium concentra-
tions during hyperparathyroidism could also affect EPO 
production. Recently, it has been shown that calcium 
antagonists such as verapamil enhance EPO production 
in response to hypoxia [37]. Furthermore, Nagakura et al. 
[38] have demonstrated that low extracellular calcium 
levels (0.3 mmol/1) in culture medium significantly in-
creased EPO production by human renal carcinoma 
cells. Recently, Washio et al. [30] have also demonstrated 
a transient increase of serum i E P O immediately after PTx 
(3-24 h) in hemodialysis patients. They observed that it 
was associated with a concomitant reduction of ionized 
serum calcium. Hypothetically, the rapid decrease of 
plasma calcium concentration after PTx could lead to a 
similar enhancement. 
Patients undergoing PTx usually receive a substitution 
therapy with vitamin D derivatives and therefore the 
question arises as to whether this hormone could be 
responsible for the rise of serum iEPO. However, our 
observation that calcitriol treatment causes a decrease 
rather than an increase of serum i E P O in uremic patients 
makes such an explanation very unlikely. 
Consequently, either a direct or indirect inhibitory 
effect of P T H on EPO production has to be considered. 
So far, the effect of P T H on EPO formation is unknown, 
and we can therefore only speculate about possible 
mechanisms. 
A direct effect of PTH on EPO production is also 
conceivable via the following pathway. Experimental 
evidence indicates that the oxygen consumption of the 
proximal renal tubule is involved in the "oxygen sensing' 
that adapts EPO production to the renal oxygen supply 
[39]. On the other hand, P T H has been shown to inhibit 
respiration and phosphorylation in kidney cortex mito-
chondria [40]. Moreover, it inhibits phosphate and bi-
carbonate reabsorption and the N a V H + exchange 
mechanism in the proximal tubule [41-45]. It is therefore 
imaginable that P T H decreases the oxygen consumption 
of the proximal tubule and thus leads to a decrease of 
EPO production since more oxygen is available. Com-
patible with this idea would be the observation that in our 
patients prior to PTx, serum E P O was inappropriately 
low in relation to the hemoglobin concentration whereas 
after PTx, serum EPO was in the range which is found in 
severely anemic patients with normal renal function [46]. 
Interestingly, the drastic reduction of circulating i P T H 
has also been demonstrated to lead to an increase of the 
plasma concentration of another polypeptide hormone, 
namely insulin, possibly via similar pathogenetic mecha-
nisms [47-49]. 
On the other hand, it has been shown that high con-
centrations of intact PTH in vitro exert an inhibitory 
effect on erythropoiesis, leading to a decrease in burst-
forming-units erythroid and the colony-forming-units 
erythroid [14]. The increase in reticulocyte count in the 
absence of change of serum i E P O after PTx, observed in 
patients with primary hyperparathyroidism might sug-
gest that erythroid progenitors of bone marrow become 
more sensitive to EPO action afic/ the reduction of 
plasma P T H . 
It is also of note that a rapid, significant increase of 
platelet count was observed after PTx in group I patients. 
This could be an expression of increased EPO produc-
tion or of some other thrombocytopoiesis-stimulating 
factor [50], possibly related to the correction of severe 
hyperparathyroidism, of the decrease of high PTH levels 
being deleterious for platelets, or of the surgical proce-
dure alone. 
Finally, the site of heavily increased EPO production 
after PTx in hemodialysis patients with terminal renal 
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failure has not been clearly established in the present 
study. Even though none of these patients was anephric, 
the residual function of renal parenchyma was almost 
certainly severely depressed, if not absent in at least some 
of them. None of the patients conserved any rejected 
renal tissue from a previous renal allograft. Therefore, 
the liver has to be considered as an alternative source of 
acute EPO production in at least part of these patients [51, 
52]. In keeping with this is the capacity of anephric 
patients to acutely induce EPO production when ex-
posed to a marked hypoxic stimulus [53]. 
In conclusion, the mechanism through which PTx leads 
to a striking increase in serum iEPO in uremic patients 
remains unclear. Acute changes of circulating PTH as well 
as of extra- or intracellular calcium and phosphorus con-
centrations after the surgical correction of severe hyperpar-
athyroidism all remain possible candidates. In contrast, the 
surgical procedure and the acute increase in plasma calcit-
riol induced by oral supplementation with active vitamin D 
derivatives do not appear to be involved. In patients with 
primary hyperparathyroidism, PTx led to an increase in 
blood reticulocytes, in the absence of a significant change 
of serum iEPO levels. This could indicate improved tissue 
sensitivity to the hormone. More study is clearly needed to 
better understand the present observations and their possi-
ble relevance for the relation between hyperparathyroidism 
and anemia. 
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